{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:36:53Z","timestamp":1787067413598,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.clinph.2021.05.018","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T11:37:36Z","timestamp":1623497856000},"page":"2184-2190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-3265","authenticated-orcid":false,"given":"Monica","family":"Alcantara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Philip","family":"Lawo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billie L.","family":"Durn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orell","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0005","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.clinph.2020.12.017","article-title":"Early axonal loss predicts long-term disability in chronic inflammatory demyelinating polyneuropathy","volume":"132","author":"Al-Zuhairy","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.clinph.2021.05.018_b0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jns.2016.11.056","article-title":"Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes","volume":"372","author":"Alabdali","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2021.05.018_b0015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jns.2016.08.034","article-title":"Disease activity in chronic inflammatory demyelinating polyneuropathy","volume":"369","author":"Albulaihe","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinph.2021.05.018_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.0781","article-title":"Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care. A review of clinical and laboratory assessment measures","author":"Allen","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1017\/S0317167100001013","article-title":"Minimum standards for electromyography in Canada: a statement of the Canadian Society of Clinical Neurophysiologists","volume":"27","author":"Bolton","year":"2000","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mus.21733","article-title":"Electrophysiologic correlations with clinical outcomes in CIDP","volume":"42","author":"Bril","year":"2010","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.clinph.2021.05.018_b0035","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1368::AID-MUS2>3.0.CO;2-7","article-title":"Electrophysiological monitoring in clinical trials","volume":"21","author":"Bril","year":"1998","journal-title":"Roche Neuropathy Study Group. Muscle Nerve"},{"key":"10.1016\/j.clinph.2021.05.018_b0040","first-page":"30469","article-title":"Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study","author":"Bril","year":"2020","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","article-title":"Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV","volume":"39","author":"Bril","year":"2009","journal-title":"Muscle Nerve"},{"issue":"3\u20134","key":"10.1016\/j.clinph.2021.05.018_b0050","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000494291","article-title":"Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"52","author":"Broers","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"8","key":"10.1016\/j.clinph.2021.05.018_b0055","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/mus.24624","article-title":"Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse","volume":"52","author":"Chin","year":"2015","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.clinph.2021.05.018_b0065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mus.26669","article-title":"Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin","volume":"60","author":"Cirillo","year":"2019","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.clinph.2021.05.018_b0070","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.clinph.2018.01.070","article-title":"Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin","volume":"129","author":"Cirillo","year":"2018","journal-title":"Clin Neurophysiol"},{"issue":"11","key":"10.1016\/j.clinph.2021.05.018_b0075","first-page":"621","article-title":"Chronic inflammatory polyradiculoneuropathy","volume":"50","author":"Dyck","year":"1975","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.clinph.2021.05.018_b0085","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/mus.21000","article-title":"Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"38","author":"Harbo","year":"2008","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.clinph.2021.05.018_b0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ene.14056","article-title":"Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study","volume":"27","author":"Hartung","year":"2020","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.clinph.2021.05.018_b0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.clinph.2021.05.018_b0100","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/jnnp-2019-320741","article-title":"Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"90","author":"Ikeda","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.clinph.2021.05.018_b0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000505234","article-title":"Electrophysiological responsiveness to long-term therapy in chronic inflammatory demyelinating polyneuropathy: case report","volume":"12","author":"Khomand","year":"2020","journal-title":"Case Rep Neurol"},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jns.12242","article-title":"Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"22","author":"Kuitwaard","year":"2017","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"10.1016\/j.clinph.2021.05.018_b0115","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/jnnp-2014-308452","article-title":"Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Kuwabara","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.clinph.2021.05.018_b0120","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp-2017-316427","article-title":"Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial","volume":"88","author":"Kuwabara","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.clinph.2021.05.018_b0125","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.clinph.2019.06.231","article-title":"Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins","volume":"130","author":"Lawley","year":"2019","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"10.1016\/j.clinph.2021.05.018_b0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and safety of Privigen(\u00ae) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)","volume":"18","author":"L\u00e9ger","year":"2013","journal-title":"J Peripher Nerv Syst"},{"issue":"9","key":"10.1016\/j.clinph.2021.05.018_b0135","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.clinph.2021.05.018_b0140","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archneurol.2011.137","article-title":"Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy","volume":"68","author":"Lin","year":"2011","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.clinph.2021.05.018_b0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinph.2021.05.018_b0150","unstructured":"Medicine AAoE. Guidelines in electrodiagnostic medicine. Recommended policy for electrodiagnostic medicine. Muscle Nerve Suppl 1999;8:S91-105."},{"issue":"4","key":"10.1016\/j.clinph.2021.05.018_b0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/bimj.200410133","article-title":"The Youden Index and the optimal cut-point corrected for measurement error","volume":"47","author":"Perkins","year":"2005","journal-title":"Biom J"},{"key":"10.1016\/j.clinph.2021.05.018_b0160","doi-asserted-by":"crossref","unstructured":"Schafflick D, Kieseier BC, Wiendl H, Meyer Zu Horste G. Novel pathomechanisms in inflammatory neuropathies. J Neuroinflammation 2017;14(1):232.","DOI":"10.1186\/s12974-017-1001-8"},{"issue":"3","key":"10.1016\/j.clinph.2021.05.018_b0165","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.clinph.2021.05.018_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.clinph.2021.05.018_b0175","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000590","article-title":"Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study","volume":"6","author":"van Schaik","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245721006040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245721006040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:04:53Z","timestamp":1761393893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245721006040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1388245721006040"],"URL":"https:\/\/doi.org\/10.1016\/j.clinph.2021.05.018","relation":{},"ISSN":["1388-2457"],"issn-type":[{"value":"1388-2457","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinph.2021.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}